Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To demonstrate efficacy of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone
versus placebo in the treatment of vasomotor symptoms after a treatment period of 3 months
and to investigate the bleeding pattern over a treatment period of one year